المؤلفون: De Greef, Axel, Ghislain, Pierre-Dominique, Bulinckx, Audrey, Coster, Alison, de Halleux, Céline, Damsin, Thomas, Jacobs, Marie-Claude, Suys, Erwin, Zoghaib, Samer, Baeck, Marie

المساهمون: UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, UCL - (SLuc) Service de dermatologie, UCL - SSS/IREC/MONT - Pôle Mont Godinne

المصدر: Clinical drug investigation, Vol. 43, no.4, p. 299-306 (2023)

مصطلحات موضوعية: Humans, Adult, Prospective Studies, Dermatitis, Atopic, Treatment Outcome, Injections, Subcutaneous, Double-Blind Method, Antibodies, Monoclonal, Severity of Illness Index, Conjunctivitis, Eczema

الوصف: Tralokinumab, the first fully human monoclonal antibody that binds specifically to interleukin-13, was safe and effective for treating atopic dermatitis (AD) in clinical trials, but real-life experience is still limited. The objective of this study was to evaluate the effectiveness and safety of tralokinumab in severe AD in a real-life multicenter prospective cohort. Adult patients with severe AD were enrolled between January 2022 and July 2022 and received tralokinumab subcutaneously for 16 weeks. Objective and subjective scores were collected at baseline, weeks 6 and 16. Adverse events were reported throughout the study. Twenty-one patients were included. An improvement of at least 75% on the Eczema Area and Severity Index (EASI 75) was achieved in 66.7% of patients at week 16. The median objective and subjective scores at week 16 were significantly (p < 0.001) lower than those at baseline. Combination with cyclosporine was sometimes necessary at the beginning of treatment, and addition of upadacitinib was required for some patients with very severe disease during the treatment. The most frequent adverse events were flares of eczema (23.8%) and reactions at injection site (19.0%). No cases of conjunctivitis were reported. Four patients (19.0%) discontinued treatment. Tralokinumab is an effective first-line biotherapy for severe AD. However, therapeutic response may be progressive. Safety data were reassuring. Atopic dermatitis flares or reactions at the injection site may lead to discontinuation of treatment. A history of conjunctivitis on dupilumab is not a contraindication to the initiation of tralokinumab.

العلاقة: boreal:278616; http://hdl.handle.net/2078.1/278616Test; info:pmid/37012527; urn:EISSN:1179-1918

الإتاحة: https://doi.org/10.1007/s40261-023-01258-7Test
http://hdl.handle.net/2078.1/278616Test

المؤلفون: De Greef, Axel, Ghislain, Pierre-Dominique, Bulinckx, Audrey, Coster, Alison, de Halleux, Céline, Damsin, Thomas, Jacobs, Marie-Claude, Suys, Erwin, Zoghaib, Samer, Baeck, Marie

المساهمون: UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, UCL - (SLuc) Service de dermatologie, UCL - SSS/IREC/MONT - Pôle Mont Godinne

المصدر: Clinical drug investigation, Vol. 43, no.4, p. 299-306 (2023)

مصطلحات موضوعية: Humans, Adult, Prospective Studies, Dermatitis, Atopic, Treatment Outcome, Injections, Subcutaneous, Double-Blind Method, Antibodies, Monoclonal, Severity of Illness Index, Conjunctivitis, Eczema

الوصف: Tralokinumab, the first fully human monoclonal antibody that binds specifically to interleukin-13, was safe and effective for treating atopic dermatitis (AD) in clinical trials, but real-life experience is still limited. The objective of this study was to evaluate the effectiveness and safety of tralokinumab in severe AD in a real-life multicenter prospective cohort. Adult patients with severe AD were enrolled between January 2022 and July 2022 and received tralokinumab subcutaneously for 16 weeks. Objective and subjective scores were collected at baseline, weeks 6 and 16. Adverse events were reported throughout the study. Twenty-one patients were included. An improvement of at least 75% on the Eczema Area and Severity Index (EASI 75) was achieved in 66.7% of patients at week 16. The median objective and subjective scores at week 16 were significantly (p < 0.001) lower than those at baseline. Combination with cyclosporine was sometimes necessary at the beginning of treatment, and addition of upadacitinib was required for some patients with very severe disease during the treatment. The most frequent adverse events were flares of eczema (23.8%) and reactions at injection site (19.0%). No cases of conjunctivitis were reported. Four patients (19.0%) discontinued treatment. Tralokinumab is an effective first-line biotherapy for severe AD. However, therapeutic response may be progressive. Safety data were reassuring. Atopic dermatitis flares or reactions at the injection site may lead to discontinuation of treatment. A history of conjunctivitis on dupilumab is not a contraindication to the initiation of tralokinumab.

العلاقة: boreal:278616; http://hdl.handle.net/2078.1/278616Test; info:pmid/37012527; urn:EISSN:1179-1918

الإتاحة: https://doi.org/10.1007/s40261-023-01258-7Test
http://hdl.handle.net/2078.1/278616Test

المؤلفون: De Greef, Axel, Dachelet, Claire, Marot, Liliane, Baeck, Marie

المساهمون: UCL - (SLuc) Service de dermatologie, UCL - (SLuc) Service d'anatomie pathologique, UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, UCL - (SLuc) Centre de malformations vasculaires congénitales, UCL - (SLuc) Centre de l'allergie

المصدر: Journal of the European Academy of Dermatology and Venereology, Vol. 36, no. 1, p. e48-e50 (2022)

مصطلحات موضوعية: Acute Disease, Adult, Edema, Exanthema, Hemorrhage, Humans

الوصف: A 49â€yearâ€old woman, with no particular medical history other than quiescent Crohn’s disease, was admitted for acute gastroenteritis. Three days after admission, she developed large purpuric, ecchymotic targetoid skin lesions and oedema, predominantly on the buttocks and thighs (Figure 1A and B). The lesions were not pruritic but slightly painful at palpation. She denied any history of vaccination or injections at the sites of the skin lesions. The patient remained afebrile. Platelet counts, coagulation tests and immunoglobulin A serum levels were within normal limits. Renal function was normal and proteinuria was excluded. Bacteriological stool samples were negative. [.]

العلاقة: boreal:262007; http://hdl.handle.net/2078.1/262007Test; info:pmid/34418184; urn:ISSN:0926-9959; urn:EISSN:1468-3083

الإتاحة: https://doi.org/10.1111/jdv.17617Test
http://hdl.handle.net/2078.1/262007Test

المؤلفون: De Greef, Axel, Coulie, Pierre G., Baeck, Marie

المساهمون: UCL - SSS/DDUV/GECE - Génétique cellulaire, UCL - SSS/IREC/LUNS - Pôle pneumologie, ORL (airways) et dermatologie (skin), UCL - (SLuc) Service de dermatologie, UCL - (SLuc) Centre de l'allergie

المصدر: Clinical immunology, Vol. 237, p. 108984 [1-3] (2022)

مصطلحات موضوعية: COVID-19, Chilblains, Humans, Pandemics, SARS-CoV-2, Skin, Cold, Pandemic, Trigger, Type 1 interferon

الوصف: The exact etiopathology of chilblains observed during the Coronavirus Disease 2019 (COVID-19) pandemic is still unclear. Initially, SARS-CoV-2 appeared as the obvious causing agent, but two years of various investigations have failed to convincingly support its direct implication. Most affected individuals have no detectable virus, no anti-SARS-CoV-2 antibodies and no symptoms of COVID-19. Analyses of skin biopsies similarly failed to unambiguously demonstrate presence of the virus or its genome. In a recent hypothesis, SARS-CoV-2 would cause the lesions before being promptly eliminated by unusually strong type I interferon responses. With others, we feel that environmental factors have not been sufficiently considered, in particular cold exposure related to unprecedented containment measures. The cause of pandemic chilblains remains a stimulating puzzle which warrants further investigation.

العلاقة: boreal:262806; http://hdl.handle.net/2078.1/262806Test; info:pmid/35338000; urn:ISSN:1521-6616; urn:EISSN:1521-7035

الإتاحة: https://doi.org/10.1016/j.clim.2022.108984Test
http://hdl.handle.net/2078.1/262806Test

المؤلفون: De Greef, Axel, Dachelet, Claire, Marot, Liliane, Baeck, Marie

المساهمون: UCL - (SLuc) Service de dermatologie, UCL - (SLuc) Service d'anatomie pathologique, UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, UCL - (SLuc) Centre de malformations vasculaires congénitales, UCL - (SLuc) Centre de l'allergie

المصدر: Journal of the European Academy of Dermatology and Venereology, Vol. 36, no. 1, p. e48-e50 (2022)

مصطلحات موضوعية: Acute Disease, Adult, Edema, Exanthema, Hemorrhage, Humans

الوصف: A 49â€yearâ€old woman, with no particular medical history other than quiescent Crohn’s disease, was admitted for acute gastroenteritis. Three days after admission, she developed large purpuric, ecchymotic targetoid skin lesions and oedema, predominantly on the buttocks and thighs (Figure 1A and B). The lesions were not pruritic but slightly painful at palpation. She denied any history of vaccination or injections at the sites of the skin lesions. The patient remained afebrile. Platelet counts, coagulation tests and immunoglobulin A serum levels were within normal limits. Renal function was normal and proteinuria was excluded. Bacteriological stool samples were negative. [.]

العلاقة: boreal:262007; http://hdl.handle.net/2078.1/262007Test; info:pmid/34418184; urn:ISSN:0926-9959; urn:EISSN:1468-3083

الإتاحة: https://doi.org/10.1111/jdv.17617Test
http://hdl.handle.net/2078.1/262007Test

المؤلفون: De Greef, Axel, Coulie, Pierre G., Baeck, Marie

المساهمون: UCL - SSS/DDUV/GECE - Génétique cellulaire, UCL - SSS/IREC/LUNS - Pôle pneumologie, ORL (airways) et dermatologie (skin), UCL - (SLuc) Service de dermatologie, UCL - (SLuc) Centre de l'allergie

المصدر: Clinical immunology, Vol. 237, p. 108984 [1-3] (2022)

مصطلحات موضوعية: COVID-19, Chilblains, Humans, Pandemics, SARS-CoV-2, Skin, Cold, Pandemic, Trigger, Type 1 interferon

الوصف: The exact etiopathology of chilblains observed during the Coronavirus Disease 2019 (COVID-19) pandemic is still unclear. Initially, SARS-CoV-2 appeared as the obvious causing agent, but two years of various investigations have failed to convincingly support its direct implication. Most affected individuals have no detectable virus, no anti-SARS-CoV-2 antibodies and no symptoms of COVID-19. Analyses of skin biopsies similarly failed to unambiguously demonstrate presence of the virus or its genome. In a recent hypothesis, SARS-CoV-2 would cause the lesions before being promptly eliminated by unusually strong type I interferon responses. With others, we feel that environmental factors have not been sufficiently considered, in particular cold exposure related to unprecedented containment measures. The cause of pandemic chilblains remains a stimulating puzzle which warrants further investigation.

العلاقة: boreal:262806; http://hdl.handle.net/2078.1/262806Test; info:pmid/35338000; urn:ISSN:1521-6616; urn:EISSN:1521-7035

الإتاحة: https://doi.org/10.1016/j.clim.2022.108984Test
http://hdl.handle.net/2078.1/262806Test

المؤلفون: De Greef, Axel, DACHELET, Claire, Marot, Liliane, Baeck, Marie

المساهمون: UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, UCL - (SLuc) Service d'anatomie pathologique, UCL - (SLuc) Service de dermatologie

المصدر: Journal of the European Academy of Dermatology and Venereology : JEADV, Vol. 36, no. 1, p. e48-e50 (2021)

مصطلحات موضوعية: Acute Disease, Adult, Edema, Exanthema, Hemorrhage, Humans

العلاقة: boreal:278601; http://hdl.handle.net/2078.1/278601Test; info:pmid/34418184; urn:EISSN:1468-3083

الإتاحة: https://doi.org/10.1111/jdv.17617Test
http://hdl.handle.net/2078.1/278601Test

المؤلفون: Hepp, Michael, Wérion, Alexis, De Greef, Axel, de Ville de Goyet, Christine, de Bournonville, Marc, Behets Wydemans, Catherine, Lengele, Benoit, Daumerie, Chantal, Mourad, Michel, Ludgate, Marian, Many, Marie-Christine, Joris, Virginie, Craps, Julie

المساهمون: UCL - SSS/IREC/MORF - Pôle de Morphologie, UCL - SSS/IREC/EDIN - Pôle d'endocrinologie, diabète et nutrition, Thyroid Research Group, Division of Infection & Immunity, Cardiff University School of Medicine - Heath Park, Cardiff CF14 4XN, UK, UCL - SSS/IREC/FATH - Pôle de Pharmacologie et thérapeutique

المصدر: International journal of molecular sciences, Vol. 22, no.8 (2021)

مصطلحات موضوعية: Adult, Autoimmune Diseases, Autoimmunity, Biomarkers, Cytokines, Female, Fluorescent Antibody Technique, Gene Expression Regulation, Hashimoto Disease, Humans, Hypoxia-Inducible Factor 1, alpha Subunit, Immunohistochemistry, Male, Middle Aged, Models, Biological, NADPH Oxidase 2, Oxidative Stress, Reactive Oxygen Species, Sirtuin 1, Superoxide Dismutase-1, T-Lymphocyte Subsets, Th1 Cells, Thymocytes, Thyroid Function Tests, Thyroid Gland, Vascular Endothelial Growth Factor A, Young Adult, HIF-1α

الوصف: In Hashimoto's thyroiditis (HT), oxidative stress (OS) is driven by Th1 cytokines' response interfering with the normal function of thyrocytes. OS results from an imbalance between an excessive production of reactive oxygen species (ROS) and a lowering of antioxidant production. Moreover, OS has been shown to inhibit Sirtuin 1 (SIRT1), which is able to prevent hypoxia-inducible factor (HIF)-1α stabilization. The aims of this study were to determine the involvement of NADPH-oxidases (NOX), SIRT1, and HIF-1α in HT pathophysiology as well as the status of antioxidant proteins such as peroxiredoxin 1 (PRDX1), catalase, and superoxide dismutase 1 (SOD1). The protein expressions of NOX2, NOX4, antioxidant enzymes, SIRT1, and HIF-1α, as well as glucose transporter-1 (GLUT-1) and vascular endothelial growth factor A (VEGF-A), were analyzed by Western blot in primary cultures of human thyrocytes that were or were not incubated with Th1 cytokines. The same proteins were also analyzed by immunohistochemistry in thyroid samples from control and HT patients. In human thyrocytes incubated with Th1 cytokines, NOX4 expression was increased whereas antioxidants, such as PRDX1, catalase, and SOD1, were reduced. Th1 cytokines also induced a significant decrease of SIRT1 protein expression associated with an upregulation of HIF-1α, GLUT-1, and VEGF-A proteins. With the exception of PRDX1 and SOD1, similar results were obtained in HT thyroids. OS due to an increase of ROS produced by NOX4 and a loss of antioxidant defenses (PRDX1, catalase, SOD1) correlates to a reduction of SIRT1 and an upregulation of HIF 1α, GLUT-1, and VEGF-A. Our study placed SIRT1 as a key regulator of OS and we, therefore, believe it could be considered as a potential therapeutic target in HT.

العلاقة: boreal:248138; http://hdl.handle.net/2078.1/248138Test; info:pmid/33916948; urn:EISSN:1422-0067

الإتاحة: https://doi.org/10.3390/ijms22083806Test
http://hdl.handle.net/2078.1/248138Test

المؤلفون: De Greef, Axel, DACHELET, Claire, Marot, Liliane, Baeck, Marie

المساهمون: UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, UCL - (SLuc) Service d'anatomie pathologique, UCL - (SLuc) Service de dermatologie

المصدر: Journal of the European Academy of Dermatology and Venereology : JEADV, Vol. 36, no. 1, p. e48-e50 (2021)

مصطلحات موضوعية: Acute Disease, Adult, Edema, Exanthema, Hemorrhage, Humans

العلاقة: boreal:278601; http://hdl.handle.net/2078.1/278601Test; info:pmid/34418184; urn:EISSN:1468-3083

الإتاحة: https://doi.org/10.1111/jdv.17617Test
http://hdl.handle.net/2078.1/278601Test